Group <40 | Group ≥40<55 | Group ≥55 | ||
---|---|---|---|---|
n=81 | n=179 | n=248 | p Value | |
Age, mean±SD, years | 33±6 | 49±5 | 66±8 | |
Women, n (%) | 61 (75) | 125 (70) | 157 (63) | 0.10 |
Smoking, no (%) | 25 (30) | 78 (44) | 74 (30) | 0.01 |
BMI, mean±SD | 24.4±4.3 | 26.6±4.5 | 26.1±3.8 | 0.001 |
Time from diagnosis to inclusion, median weeks (IQR) | 1.6 (0.7–3.1) | 2.4 (1.0–5.3) | 2.7 (1.0–4.7) | 0.004 |
Symptom duration, median weeks (IQR) | 26.1 (13.4–57.9) | 24.6 (15.3–56.1) | 22.4 (13.3–44.3) | 0.25 |
RF positive, n (%) | 53 (65) | 123 (69) | 153 (62) | 0.32 |
ACPA positive, n/total n (%) | 43/78 (55) | 116/169 (69) | 132/226 (58) | 0.05 |
DAS, mean±SD | 4.4±0.9 | 4.3±0.8 | 4.5±0.9 | 0.12 |
HAQ score, 0–3 scale, mean±SD | 1.3±0.7 | 1.4±0.6 | 1.4±0.7 | 0.49 |
CRP, mean±SD | 35.4±43.2 | 32.8±41.9 | 41.1±43.2 | 0.14 |
ESR, mean±SD | 37.1±25.4 | 34.7±25.7 | 45.8±28.4 | <0.001 |
Ritchie Articular Index | 14 (9–20) | 13 (10–17) | 13 (9–18) | 0.53 |
Swollen joint count | 14 (10–18) | 12 (9–18) | 14 (10–19) | 0.06 |
Total SHS (0–448 scale) | ||||
Median (IQR) | 1.0 (0.0–3.0) | 1.0 (0.0–4.5) | 2.5 (1.0–7.4) | <0.001 |
Mean±SD | 2.4±3.7 | 3.1±4.9 | 5.0±6.8 | |
Erosion score, 0–280 scale | ||||
Median (IQR) | 0.0 (0.0–0.3) | 1.0 (0.0–3.0) | 0.0 (0.0–1.0) | <0.001 |
Mean±SD | 0.5±1.4 | 0.9±2.6 | 1.1±2.0 | |
JSN score, 0–168 scale | ||||
Median (IQR) | 0.3 (0.0–3.0) | 1.0 (0.0–3.0) | 2.0 (0.0–6.0) | <0.001 |
Mean±SD | 1.9±2.9 | 2.2±3.2 | 3.9±5.5 | |
Treatment strategy | ||||
Sequential monotherapy, n (%) | 19 (24) | 51 (29) | 56 (23) | 0.52 |
Step-up therapy, n (%) | 18 (22) | 47 (26) | 56 (23) | |
Initial combination therapy with prednisone, n (%) | 22 (27) | 45 (25) | 66 (27) | |
Initial combination therapy with infliximab, n (%) | 22 (27) | 36 (20) | 70 (28) |
ACPA, anticitrullinated protein antibodies; CRP, C reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; JSN, joint space narrowing; RF, rheumatoid factor; SHS, Sharp/van der Heijde score.